TCHP: A Mitochondrial Protein with Oncostatic Activity as a Potential Drug Target

Target Name: TCHP

NCBI ID: G84260

TCHP

TCHP: A Mitochondrial Protein with Oncostatic Activity as a Potential Drug Target

Mitochondria are organelles responsible for generating energy in the form of ATP during cellular metabolism. They are also involved in the production of various molecules, including proteins, which play crucial roles in the cell's survival and function. One such protein is TCHP (TCA-containing protein), which has been identified as a potential drug target in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders.

TCHP: Structure and Function

TCHP is a protein that contains a unique conformational switch located in its N-terminus. This switch allows TCHP to exist in two distinct forms: a cytoplasmic form and a mitochondrial form. The cytoplasmic form is expressed in various cell types, including neurons, while the mitochondrial form is primarily localized to the mitochondrial inner membrane.

TCHP functions as a structural protein that plays a critical role in the stability and localization of various proteins in the mitochondrial system. Its unique structure allows it to interact with multiple cellular components, including other proteins, organelles, and molecules.

TCHP's oncostatic activity

Oncostatic activity is a phenomenon in which TCHP can induce the mitochondrial outer membrane (MOM) to translocate into the cytoplasm, leading to the formation of a mitochondrial-associated protein complex (MAPP) and the disruption of the mitochondrial integrity. This process is critical for the execution of various cellular processes, including the entry of nutrients, toxins, and diseases into the mitochondria.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, the misfolded and aggregated proteins that accumulate in the brain contribute to the progressive neurotoxicity associated with the disease. TCHP's oncostatic activity has been implicated in the pathogenesis of these diseases, as it has been shown to contribute to the misfolding and localization of damaged proteins in the brain.

TCHP as a drug target

TCHP's oncostatic activity makes it an attractive drug target for various neurodegenerative diseases. By targeting TCHP's activity, researchers have the potential to develop new therapeutic strategies that can modulate the misfolding and localization of damaged proteins in the brain and potentially slow down or reverse the progression of neurodegenerative diseases.

One approach to targeting TCHP is through small molecule inhibitors that can modulate its oncostatic activity. Such inhibitors have been shown to be effective in preclinical studies in treating various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

Another approach to targeting TCHP is through the use of monoclonal antibodies (MCAs), which are laboratory-produced molecules that mimic the function of natural antibodies. MCAs can be used to specifically target TCHP and its oncostatic activity, and are currently being developed as a potential new therapeutic approach for various neurodegenerative diseases.

Conclusion

TCHP is a protein that plays a critical role in the stability and localization of various proteins in the mitochondrial system. Its oncostatic activity, which involves the formation of a mitochondrial-associated protein complex and the disruption of mitochondrial integrity, has been implicated in the pathogenesis of various neurodegenerative diseases. As such, TCHP is an attractive drug target for the development of new therapeutic strategies for the treatment of neurodegenerative diseases.

small molecule inhibitors, monoclonal antibodies, TCHP, mitochondrial protein, oncostatic activity, neurodegenerative diseases, drug target, therapeutic strategies

Protein Name: Trichoplein Keratin Filament Binding

Functions: Tumor suppressor which has the ability to inhibit cell growth and be pro-apoptotic during cell stress. Inhibits cell growth in bladder and prostate cancer cells by a down-regulation of HSPB1 by inhibiting its phosphorylation. May act as a 'capping' or 'branching' protein for keratin filaments in the cell periphery. May regulate K8/K18 filament and desmosome organization mainly at the apical or peripheral regions of simple epithelial cells (PubMed:15731013, PubMed:18931701). Is a negative regulator of ciliogenesis (PubMed:25270598)

The "TCHP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCHP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets